Daniel Vitt - 04 Mar 2024 Form 4 Insider Report for IMMUNIC, INC. (IMUX)

Role: President and CEO, Director
Signature: /s/ Daniel Vitt
Issuer symbol: IMUX
Transactions as of: 04 Mar 2024
Net transactions value: $0
Form type: 4
Filing time: 06 Mar 2024, 21:51:27 UTC
Previous filing: 28 Feb 2024
Next filing: 06 Dec 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMUX	Stock Option	Disposed to Issuer	-65,000	-100%	0	04 Mar 2024	Common Stock	65,000	$13.29	Direct	F1
transaction	IMUX	Stock Option	Disposed to Issuer	-80,000	-100%	0	04 Mar 2024	Common Stock	80,000	$12.30	Direct	F1
transaction	IMUX	Stock Option	Disposed to Issuer	-115,000	-100%	0	04 Mar 2024	Common Stock	115,000	$15.72	Direct	F1
transaction	IMUX	Stock Option	Disposed to Issuer	-215,000	-100%	0	04 Mar 2024	Common Stock	215,000	$10.73	Direct	F1
transaction	IMUX	Stock Option	Disposed to Issuer	-10,000	-100%	0	04 Mar 2024	Common Stock	10,000	$3.40	Direct	F1
transaction	IMUX	Stock Option	Award	+485,000		485,000	04 Mar 2024	Common Stock	485,000	$1.72	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

Content

On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.